The Fort Worth Press - Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

USD -
AED 3.67325
AFN 63.000155
ALL 83.300127
AMD 377.180904
ANG 1.790083
AOA 916.999757
ARS 1394.448599
AUD 1.417655
AWG 1.8025
AZN 1.6971
BAM 1.704371
BBD 2.014946
BDT 122.754882
BGN 1.709309
BHD 0.377732
BIF 2970
BMD 1
BND 1.283525
BOB 6.913501
BRL 5.246299
BSD 1.000436
BTN 93.206388
BWP 13.651833
BYN 3.093542
BYR 19600
BZD 2.012088
CAD 1.372575
CDF 2270.000396
CHF 0.791235
CLF 0.023156
CLP 914.379684
CNY 6.87305
CNH 6.89632
COP 3703.61
CRC 468.079358
CUC 1
CUP 26.5
CVE 97.049984
CZK 21.22835
DJF 178.150177
DKK 6.480435
DOP 58.950413
DZD 132.005031
EGP 52.2452
ERN 15
ETB 156.999641
EUR 0.86741
FJD 2.23025
FKP 0.750673
GBP 0.747055
GEL 2.715039
GGP 0.750673
GHS 10.904968
GIP 0.750673
GMD 73.999876
GNF 8779.999841
GTQ 7.652926
GYD 209.305771
HKD 7.83277
HNL 26.570028
HRK 6.531202
HTG 131.227832
HUF 339.5165
IDR 16947
ILS 3.121905
IMP 0.750673
INR 93.20245
IQD 1310
IRR 1314999.999833
ISK 124.749962
JEP 0.750673
JMD 157.168937
JOD 0.708999
JPY 158.280503
KES 129.549677
KGS 87.447903
KHR 4010.000373
KMF 428.000031
KPW 899.987979
KRW 1495.759743
KWD 0.30655
KYD 0.833751
KZT 481.121429
LAK 21449.999666
LBP 89549.999831
LKR 311.846652
LRD 183.349858
LSL 16.820347
LTL 2.95274
LVL 0.60489
LYD 6.380056
MAD 9.37375
MDL 17.532561
MGA 4169.999987
MKD 53.541262
MMK 2099.739449
MNT 3585.842291
MOP 8.07209
MRU 40.11977
MUR 46.509725
MVR 15.45991
MWK 1735.999806
MXN 17.82539
MYR 3.939504
MZN 63.90203
NAD 16.820186
NGN 1356.496902
NIO 36.720261
NOK 9.50675
NPR 149.125498
NZD 1.711029
OMR 0.384488
PAB 1.000471
PEN 3.427497
PGK 4.302749
PHP 59.907065
PKR 279.298917
PLN 3.70548
PYG 6500.777741
QAR 3.643992
RON 4.426802
RSD 101.887676
RUB 85.999263
RWF 1459
SAR 3.75469
SBD 8.04524
SCR 14.217553
SDG 600.99976
SEK 9.336502
SGD 1.280125
SHP 0.750259
SLE 24.650087
SLL 20969.510825
SOS 571.498731
SRD 37.375029
STD 20697.981008
STN 21.5
SVC 8.753927
SYP 110.528765
SZL 16.820303
THB 32.775498
TJS 9.579415
TMT 3.5
TND 2.9175
TOP 2.40776
TRY 44.318502
TTD 6.781035
TWD 31.891704
TZS 2597.513194
UAH 43.994632
UGX 3781.362476
UYU 40.523406
UZS 12174.999707
VES 450.94284
VND 26290
VUV 119.408419
WST 2.73222
XAF 571.660014
XAG 0.014177
XAU 0.000217
XCD 2.70255
XCG 1.803034
XDR 0.710959
XOF 566.499323
XPF 103.901218
YER 238.575027
ZAR 16.857025
ZMK 9001.199188
ZMW 19.584125
ZWL 321.999592
  • GSK

    0.1600

    52.22

    +0.31%

  • RELX

    -0.2450

    33.615

    -0.73%

  • AZN

    -0.1390

    188.281

    -0.07%

  • RYCEF

    -0.5900

    16.01

    -3.69%

  • NGG

    -1.9000

    85.5

    -2.22%

  • RBGPF

    -13.5000

    69

    -19.57%

  • RIO

    -2.9700

    84.75

    -3.5%

  • CMSC

    0.0210

    22.851

    +0.09%

  • BCE

    -0.1300

    25.62

    -0.51%

  • CMSD

    0.0600

    22.95

    +0.26%

  • BCC

    -2.9300

    68.91

    -4.25%

  • JRI

    -0.1380

    12.185

    -1.13%

  • VOD

    -0.0140

    14.356

    -0.1%

  • BTI

    0.4150

    58.505

    +0.71%

  • BP

    1.5700

    46.18

    +3.4%

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share

TAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain, today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.

Text size:

In addition, the Company issued an aggregate of 10,000,000 warrants to purchase shares of common stock at an exercise price of $0.01 per share (the "Warrants"), which were issued as additional consideration in connection with the conversion. The Warrants are exercisable immediately, have a term of 5 years from issuance, and are subject to customary anti-dilution adjustments.

This conversion, which was approved by the disinterested directors of the Board, reflects Mr. Patel's confidence in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Patel's belief in the Company's long-term success, the newly issued shares of the Company's common stock are subject to a lock-up agreement restricting transfers for a period of 6 months, subject to customary exceptions.

The structure of the transaction, including the issuance of Warrants, was designed to align management and director incentives with long-term shareholder value creation.

"I believe Wellgistics has the potential to build upon its vision and bring long lasting value to all healthcare stakeholders," said Mr. Patel. "This conversion reinforces my unwavering belief in our team, our mission, and the transformative impact we will have on the future of healthcare."

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the expected benefits of the debt conversion transaction, including its anticipated impact on the Company's balance sheet, liquidity, capitalization, and alignment of management and director interests with those of stockholders, as well as the Company's strategic plans, growth initiatives, and long-term value creation.

In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology. These statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These risks and uncertainties include, without limitation, risks related to the Company's ability to realize the anticipated benefits of the debt conversion transaction; the potential dilutive impact of the issuance of common stock and warrants, including upon exercise of the warrants; the Company's ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the Company's stock price; the Company's ability to execute its business strategy and growth initiatives; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Wellgistics Media & Investor Contact

Media:
[email protected]

Investor Relations:
[email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

S.Rocha--TFWP